Search by Medical Condition

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

Clinical Trials for Immunoglobulin Light-chain Amyloidosis

• Optimize First-line Treatment for AL Amyloidosis With t (11; 14)
• A Study to Investigate Safety and Efficacy With SAR445514 in Participants With Relapsed/Refractory Multiple Myeloma (RRMM) and Relapsed/Refractory Light-chain Amyloidosis (RRLCA)
• Probiotic Supplementation Reduces Gastrointestinal Symptoms During the Therapy and Improves Therapeutic Response in AL Amyloidosis
• Venetoclax, Daratumumab, and Dexamethasone for Systemic Light-Chain Amyloidosis With Translocation (11;14) (ALTITUDE)
• Venetoclax-Dexamethasone in Relapsed and/or Refractory t(11;14) Amyloidosis
• Phase 1/2 Study of ZN-d5 for the Treatment of Relapsed or Refractory Light Chain (AL) Amyloidosis
• Efficacy of [18F]Florbetaben PET for Diagnosis of Cardiac AL Amyloidosis
• Phase I/IIa Study of Belantamab Mafodotin in Relapsed or Refractory AL Amyloidosis
• Isatuximab Plus Pomalidomide and Dexamethasone Association for Patients With AL Amyloidosis Not in VGPR or Better After Any Previous Therapy
• COVID-19 VAX Booster Dosing in Patients With Hematologic Malignancies
• Selinexor for Treatment of Light Chain Amyloidosis With Relapsed/Refractory Disease
• Daratumumab and Pomalidomide in Previously Treated Patients With AL Amyloidosis
• Venetoclax, MLN9708 (Ixazomib Citrate) and Dexamethasone for the Treatment of Relapsed or Refractory Light Chain Amyloidosis
• Isatuximab as Upfront Therapy for the Treatment of High Risk AL Amyloidosis
• A Study of Belantamab Mafodotin in Patients With Relapsed or Refractory AL Amyloidosis
• Comparison of BTD and BCD Based Regimens in the Treatment of AL Amyloidosis
• A Study to Evaluate the Effectiveness and Safety of CAEL-101 in Patients With Mayo Stage IIIa AL Amyloidosis
• A Study to Evaluate the Effectiveness and Safety of CAEL-101 in Patients With Mayo Stage IIIb AL Amyloidosis
• Novel Imaging Tools in Newly-diagnosed Patients With Cardiac AL Amyloidosis
• A Study to Evaluate the Safety and Tolerability of CAEL-101 in Patients With AL Amyloidosis
• Frontline Lenalidomide for AL Amyloidosis Involving Myocardium
• Daratumumab, Pomalidomide, and Dexamethasone (DPd) in Relapsed/Refractory Light Chain Amyloidosis Patients Previously Exposed to Daratumumab
• A Clinical Study of Melphalan Flufenamide (Melflufen) and Dexamethasone for Patients With Immunoglobulin Light Chain (AL) Amyloidosis
• Ixazomib Maintenance Study in Patients With AL Amyloidosis
• A Trial of Doxycycline vs. Standard Supportive Therapy in Newly-diagnosed Cardiac AL Amyloidosis Patients Undergoing Bortezomib-based Therapy
• Siltuximab to Decrease Symptom Burden After Autologous Stem Cell Transplantation for Patients With Multiple Myeloma and AL Amyloidosis
• Daratumumab, Ixazomib, and Dexamethasone in AL Amyloidosis
• Lenalidomide, Dexamethasone, and Elotuzumab With or Without Cyclophosphamide in Treating Patients With Relapsed Primary Amyloidosis
• Ixazomib In Combination With Cyclophosphamide And Dexamethasone for Newly Diagnosed AL Amyloidosis
• Study in Subjects With Light Chain (AL) Amyloidosis
• Ibrutinib With or Without Bortezomib and Dexamethasone in Treating Patients With Relapsed or Refractory Immunoglobulin Light Chain Amyloidosis
• Trial of Venetoclax (ABT-199) and Dexamethasone for Relapsed or Refractory Systemic AL Amyloidosis
• Propylene Glycol-Free Melphalan Hydrochloride (Evomela) in AL Amyloidosis Patients
• Daratumumab for the Treatment of Patients With AL Amyloidosis
• Daratumumab Therapy for Patients With Refractory or Relapsed AL Amyloidosis
• The PRONTO Study, a Global Phase 2b Study of NEOD001 in Previously Treated Subjects With Light Chain (AL) Amyloidosis
• Open-label Extension Study of NEOD001 in Subjects With Light Chain (AL) Amyloidosis
• A Dose Escalation Study of Carfilzomib Taken With Thalidomide and Dexamethasone in Relapsed AL Amyloidosis
• Trial of High Dose Melphalan/Stem Cell Transplant With or Without Bortezomib
• Study of Chimeric Fibril-Reactive Monoclonal Antibody 11-1F4 in Patients With AL Amyloidosis
• Doxycycline to Upgrade Organ Response in Light Chain (AL) Amyloidosis Trial
• Bortezomib and Dexamethasone Followed by ASCT Compared With ASCT Alone in Treating Patients With AL Amyloidosis
• Autologous Stem Cell Transplant Followed By Maintenance Therapy in Treating Elderly Patients With Multiple Myeloma
• Pomalidomide With Melphalan and Dexamethasone for Untreated Systemic AL Amyloidosis
• First-line Pomalidomide, Bortezomib, and Dexamethasone For AL Amyloidosis or LCDD
• Phase 1/2, Open Label, Dose Escalation Study of NEOD001 in Subjects With Light Chain (AL) Amyloidosis
• A Phase I/II Trial of Pomalidomide and Dexamethasone in Subjects With Previously-Treated AL Amyloidosis
• High Cut-off Hemodialysis in Patients With Advanced Cardiac AL Amyloidosis and End Stage Renal Disease
• Epigallocatechingallate (EGCG) in Cardiac AL Amyloidosis
• Pomalidomide and Dexamethasone (PDex) in AL Amyloidosis
• Bortezomib/Dexamethasone (BD), Followed By Autologous Stem Cell Transplantation and Maintenance Bortezomib/Dexamethasone For the Initial Treatment of Monoclonal Immunoglobulin Deposition Disease (MIDD) Associated With Multiple Myeloma and AL Amyloid
• A Trial for Systemic Light-chain (AL) Amyloidosis
• Bendamustine and Dexamethasone in Patients With Relapsed AL Amyloidosis
• Infection Prophylaxis and Management in Treating Cytomegalovirus (CMV) Infection in Patients With Hematologic Malignancies Previously Treated With Donor Stem Cell Transplant
• Lendexal in Patients With Primary Systemic Amyloidosis (AL) Newly Diagnosed
• Melphalan and Dexamethasone With or Without Bortezomib in Treating Patients With Previously Untreated Systemic Light-Chain Amyloidosis
• Bortezomib, Cyclophosphamide, and Dexamethasone in Treating Patients With Primary Systemic Light Chain Amyloidosis
• Sunitinib Malate in Treating HIV-Positive Patients With Cancer Receiving Antiretroviral Therapy
• A Pilot Study of Lenalidomide, Melphalan and Dexamethasone in AL Amyloidosis
• A Trial of Treatment With Lenalidomide-Melphalan-Dexamethasone in Patients With Primary (AL) Amyloidosis
• Melphalan, Bortezomib, and Stem Cell Transplant in Treating Patients With Primary Systemic Amyloidosis
• Melphalan, Lenalidomide, and Dexamethasone in Treating Patients With Primary Systemic Amyloidosis
• Trial of Two Stem Cell Doses To Reduce Transplant Induced Symptom Burden
• Cyclophosphamide, Lenalidomide and Dexamethasone (CLD) for Previously Treated Patients With AL Amyloidosis
• Lenalidomide, Cyclophosphamide, and Dexamethasone in Treating Patients With Primary Systemic Amyloidosis
• High-Dose Chemotherapy With or Without Total-Body Irradiation Followed by Autologous Stem Cell Transplant in Treating Patients With Hematologic Cancer or Solid Tumors
• Bortezomib, Melphalan, and Dexamethasone in Treating Patients With Primary Amyloidosis or Light Chain Deposition Disease
• Low-Dose Melphalan and Dexamethasone Compared With High-Dose Melphalan Followed By Autologous Stem Cell Transplant in Treating Patients With Primary Systemic Amyloidosis
• Intensive Versus Conventional Treatment in Patients With Primary Amyloidosis
• Phase II Trial of Enbrel in Patients With Primary Systemic Amyloidosis
• Efficacy of CC-5013 (Revlimid or Lenalidomide) in Patients With Primary Systemic Amyloidosis
• Fludarabine and Total-Body Irradiation Followed By Donor Stem Cell Transplant and Cyclosporine and Mycophenolate Mofetil in Treating HIV-Positive Patients With or Without Cancer
• CC-5013 With or Without Dexamethasone in Treating Patients With Primary Systemic Amyloidosis
• Melphalan, Thalidomide, and Dexamethasone in Treating Patients With Newly Diagnosed, Previously Untreated Primary Systemic Amyloidosis
• S0115, High-Dose Melphalan and Autologous Peripheral Stem Cell Transplantation in Treating Patients With Multiple Myeloma or Primary Systemic Amyloidosis
• Amifostine and Melphalan in Treating Patients With Primary Systemic Amyloidosis Who Are Undergoing Peripheral Stem Cell Transplantation
• Iododoxorubicin in Treating Patients With Primary Systemic Amyloidosis
• Imatinib Mesylate in Treating Patients With Advanced Cancer and Liver Dysfunction
• Fludarabine Phosphate and Total-Body Radiation Followed by Donor Peripheral Blood Stem Cell Transplant and Immunosuppression in Treating Patients With Hematologic Malignancies
• Fludarabine and Total-Body Irradiation Followed By Donor Stem Cell Transplant and Cyclosporine and Mycophenolate Mofetil in Treating HIV-Positive Patients With or Without Cancer
• Chemotherapy Plus Peripheral Stem Cell Transplant in Treating Patients Who Have Multiple Myeloma or Primary Systemic Amyloidosis
• Fludarabine Phosphate, Low-Dose Total-Body Irradiation, and Donor Stem Cell Transplant Followed by Cyclosporine, Mycophenolate Mofetil, Donor Lymphocyte Infusion in Treating Patients With Hematopoietic Cancer
• 4'-Iodo-4'-Deoxydoxorubicin in Treating Patients With Primary Systemic Amyloidosis
• High-Dose Melphalan Plus Peripheral Stem Cell Transplantation in Treating Patients With Primary Systemic Amyloidosis
• S9628 Dexamethasone Plus Interferon Alfa in Treating Patients With Primary Systemic Amyloidosis